What conditions has it actually been studied in?

Real randomized trials and meta-analyses exist in chronic hepatitis B, severe sepsis, severe acute pancreatitis, cancer as a chemotherapy/vaccine adjuvant, and COVID-19. Results are mixed: some trials are positive, others (such as the pancreatitis RCT) were negative or inconclusive.

Does it cure infections or cancer by itself?

No. It is an immunomodulator studied as an adjuvant that aims to strengthen the host immune response alongside standard therapy, not as a direct antiviral or antitumor drug used on its own.

How strong is the evidence overall?

It is genuinely mixed. Several meta-analyses suggest benefits in sepsis and infection, but they repeatedly note that the pooled trials are small or of low methodological quality, so conclusions remain tentative and larger high-quality trials are still needed.

In the populations studied it has generally been well tolerated, with injection-site reactions being most common. However, because it stimulates the immune system, its safety in autoimmune disease, transplant, or immunosuppressed settings is not established, and it should only be used under medical supervision.

EMA-approved

Thymosin alpha-1 — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Thymosin alpha-1 is a peptide catalogued under Immune. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Thymosin alpha-1?

Thymosin alpha-1 (thymalfasin, brand name Zadaxin) is a 28-amino-acid synthetic immunomodulatory peptide derived from thymosin fraction 5, used to broadly stimulate T-cell and dendritic-cell function.

It is approved or registered in more than 30 countries (including China, Italy, and several others) for chronic hepatitis B, as a vaccine adjuvant, and as a cancer/sepsis adjuvant, but it is NOT fully FDA-approved in the United States (only granted orphan-drug status for select indications).

Human evidence is genuinely mixed: multiple randomized trials and meta-analyses exist in chronic hepatitis B, sepsis, and COVID-19, but many are small, single-region, or of low-to-moderate methodological quality, so benefits remain suggestive rather than definitively established.

How does Thymosin alpha-1 work?

Thymosin alpha-1 modulates innate and adaptive immunity primarily by signaling through Toll-like receptors (notably TLR2 and TLR9) on dendritic cells and monocytes, promoting T-helper-1 differentiation, cytotoxic T-cell activity, and natural-killer-cell function.

It does not directly kill pathogens or tumor cells; instead it aims to restore or amplify a host immune response, which is why it is studied as an adjuvant rather than a standalone therapy. [INFOGRAPHIC: Thymosin alpha-1 immune modulation via TLRs]

What does the research say about Thymosin alpha-1?

In severe sepsis, the multicenter ETASS randomized controlled trial (n=361) reported a lower 28-day all-cause mortality with thymosin alpha-1 versus placebo, but the effect was modest and the trial was underpowered to be definitive, so it is best read as hypothesis-supporting rather than conclusive. ^[1]
In chronic hepatitis B, a randomized controlled trial found that thymosin alpha-1 combined with interferon-alpha improved virological/biochemical response compared with monotherapy, consistent with a real but adjunctive antiviral-immune benefit. ^[2]
A systematic review and meta-analysis of thymosin alpha-1 in sepsis suggested a reduction in mortality, but the authors explicitly graded the underlying evidence as low quality and called for larger high-quality trials, so the pooled signal should be interpreted cautiously. ^[5]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — Wu J et al., Crit Care 2013. (RCT n=361 (multicenter))
[2] Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study — You J et al., World J Gastroenterol 2006. (RCT (comparative))
[3] Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial — Ke L et al., Intensive Care Med 2022. (RCT (multicenter, double-blind))
[4] Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study — Liu J et al., Front Immunol 2021. (observational cohort (not an RCT))
[5] Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis — Li C et al., Int J Infect Dis 2015. (systematic review / meta-analysis)
[6] Ulinastatin- and thymosin alpha1-based immunomodulatory strategy for sepsis: A meta-analysis — Han D et al., Int Immunopharmacol 2015. (meta-analysis)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In published clinical trials, thymalfasin is most commonly administered as a 1.6 mg subcutaneous injection given once or twice weekly (hepatitis) or daily (sepsis/critical illness) under medical supervision, with regimens varying widely by indication.

These figures describe how the drug was studied in registered trials and are provided for context only, not as a recommendation for use.

Side effects & safety profile

Across trials thymosin alpha-1 has generally been well tolerated, with injection-site reactions being the most commonly reported adverse events and no consistent signal for serious drug-specific toxicity in the studied populations.

Because it stimulates immune activity, its safety in autoimmune disease, transplant recipients, or those on immunosuppressants is not established, and it should be regarded as a research/clinical compound requiring medical supervision.

Long-term safety data outside of the specific approved indications and trial settings are limited.

Stacking & combinations

In trials it has been combined with interferon-alpha (hepatitis), standard sepsis care, and cancer chemotherapy/vaccines as an immune adjuvant rather than used as a standalone agent.

Finding Thymosin alpha-1 vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

No. It is approved or registered in more than 30 countries (for example China and Italy) for indications such as chronic hepatitis B and as an immune adjuvant, but it does not hold full FDA marketing approval in the United States, where it has only received orphan-drug designation for certain conditions.

References

[1] The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial — Wu J et al., Crit Care 2013. PMID: 23327199. View sourceStudy: RCT n=361 (multicenter)Thymosin alpha-1 was associated with lower 28-day all-cause mortality versus placebo in severe sepsis, though the effect was modest.
[2] Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study — You J et al., World J Gastroenterol 2006. PMID: 17075991. View sourceStudy: RCT (comparative)Thymosin alpha-1 combined with interferon-alpha improved treatment response compared with monotherapy in chronic hepatitis B.
[3] Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial — Ke L et al., Intensive Care Med 2022. PMID: 35713670. View sourceStudy: RCT (multicenter, double-blind)Thymosin alpha-1 immune enhancement did not significantly reduce the incidence of infected pancreatic necrosis versus placebo, an important negative/inconclusive result.
[4] Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study — Liu J et al., Front Immunol 2021. PMID: 34408744. View sourceStudy: observational cohort (not an RCT)Thymosin alpha-1 was associated with reduced mortality in a COVID-19 cohort, but the observational design limits causal inference.
[5] Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis — Li C et al., Int J Infect Dis 2015. PMID: 25532482. View sourceStudy: systematic review / meta-analysisPooled analysis suggested a mortality reduction in sepsis but rated the evidence as low quality, warranting larger trials.
[6] Ulinastatin- and thymosin alpha1-based immunomodulatory strategy for sepsis: A meta-analysis — Han D et al., Int Immunopharmacol 2015. PMID: 26522590. View sourceStudy: meta-analysisCombined ulinastatin plus thymosin alpha-1 was associated with lower mortality in sepsis, though heterogeneity and trial quality limit certainty.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.